Final results of the CLL2-BAAG trial: acalabrutinib, venetoclax, and obinutuzumab triplet in R/R CLL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-01-23
Просмотров: 157
Описание:
Moritz Fürstenau, MD, University Hospital of Cologne, Cologne, Germany, discusses the final results of the CLL2-BAAG trial (NCT03787264), a Phase II study investigating the triple combination of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Fürstenau highlights that the measurable residual disease (MRD)-negative remission rate increased over time, with over 90% of patients achieving undetectable MRD. Remissions were long-lasting, with over 80% of patients remaining progression-free after three years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
